SCYX Up to $214M BARDA Contract for SCY-247 Antifungal

SCYNEXIS (Nasdaq: SCYX) just secured a contract from BARDA, the U.S. government’s biomedical preparedness arm, worth up to $214 million in non-dilutive funding to advance SCY-247, its second-generation “fungerp” antifungal. The base period commits only about $18.5 million to move oral and intravenous SCY-247 into a Phase 2 trial in invasive candidiasis. The remaining funding is released only if BARDA exercises options over a contract that can run up to 10 years.

SCYX shares closed at $4.62 on Monday, up about 5% from the prior close of $4.39, on volume of roughly 7.8 million shares. The move is modest because the market understands the headline is a ceiling, not a check. With a market cap near $43.7 million, the “$214 million” figure is nearly five times the company’s entire value, but today only $18.5 million is committed under a cost-share arrangement.

Mechanism: Why the Fungerp Class Exists

SCY-247 is a triterpenoid in the same novel structural class as SCYNEXIS’s first drug, BREXAFEMME (ibrexafungerp), which GSK licensed as the first approved “fungerp.” The mechanism differs from the azoles and echinocandins that dominate antifungal treatment: instead of inhibiting ergosterol synthesis (azoles) or glucan synthesis (echinocandins), fungerps directly target the glucan synthase complex in a way that kills fungal cells outright — a fungicidal mechanism that is not subject to the resistance pathways that have eroded the azole class, and one that shows in-vitro activity against fungal strains resistant to existing therapies.

Both oral and IV formulations are part of the plan, which matters clinically: invasive candidiasis often starts in hospitalized patients on IV therapy, but step-down to oral dosing lets patients finish treatment at home. Echinocandins have no oral form; a fungerp that can do both ends of that journey would be the first of its kind, and that pharmacokinetic flexibility is precisely what BARDA preparedness planners want in a stockpiled agent.

BARDA’s interest is antimicrobial resistance (AMR): invasive fungal infections carry limited treatment options and rising resistance. Invasive candidiasis is the most common invasive fungal infection in U.S. hospitals; the CDC estimates roughly 25,000 cases of candidemia each year, with in-hospital mortality around one in three. Add emerging drug-resistant threats like Candida auris in long-term care facilities, and the preparedness case writes itself. The contract funds development for two indications, treating invasive candidiasis and preventing invasive fungal infections in high-risk patients, through NDA submission if all options are exercised.

What It Means for the Trade

The award matters for two reasons. It validates the fungerp class as strategically important for U.S. preparedness against drug-resistant fungal disease, a signal with real weight for a $43.7 million microcap. And it gives SCYNEXIS a non-dilutive path to develop SCY-247 without selling equity, which is valuable for a company still funded largely by development milestones. For a stock at $4.62, the removal of a financing overhang is arguably worth more than the headline dollar figure.

There is a second pipeline thread. CEO David Angulo noted the company remains focused on SCY-770, a new candidate for autosomal dominant polycystic kidney disease. That suggests SCY-247 is not the only bet, and the BARDA funding lets the antifungal advance without competing for scarce internal cash.

The timeline is long but legible: Phase 2 in invasive candidiasis first, with option exercises gating each subsequent phase. Each BARDA option exercised is a discrete, news-drivable event, and preparedness contracts historically do get exercised when the underlying data cooperate — BARDA does not sign 10-year structures for programs it expects to abandon.

Risks and What Could Go Wrong

The gap between “$18.5 million committed” and “$214 million possible” is the whole story, and it will stay open until the data reads out. If SCY-247 underwhelms in Phase 2 — invasive candidiasis trials have real mortality endpoints and echinocandins are a competent comparator — BARDA can simply stop exercising options, and the contract’s headline value evaporates without a breach of anything.

The cost-share structure means SCYNEXIS still contributes its own cash; $18.5 million committed does not mean zero burn from the company side. A microcap running two programs (SCY-247 and SCY-770) on milestone-dependent funding is one slow quarter away from another raise, non-dilutive contract or not.

The commercial market also deserves honesty: even approved, hospital antifungals face generic echinocandins and payer pressure. A preparedness stockpile purchase is a plausible revenue model — BARDA buys what it funds — but commercial uptake in U.S. hospitals is a slower, harder sale. What to watch next is whether BARDA exercises options beyond the base period, and how quickly SCY-247 clears the Phase 2 bar in invasive candidiasis. The full announcement is on the company’s investor site.